Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired factor V inhibitors.

P Knöbl1, K Lechner

  • 1Department of Medicine I, University of Vienna, Austria.

Bailliere'S Clinical Haematology
|March 31, 1999
PubMed
Summary
This summary is machine-generated.

Factor V inhibitors, while having a generally good prognosis, vary in outcome by cause. Bovine thrombin exposure offers the best outlook, whereas

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Erratum to: Saturated fatty acids and cardiovascular risk: Is a revision of the recommendations on nutrition indicated?]

Herz·2021
Same author

[Saturated fatty acids and cardiovascular risk : Is a revision of the recommendations on nutrition indicated?]

Herz·2021
Same author

Hydrothermally modified slow release corn starch: a potential new therapeutic option for treating hypoglycemia in autoimmune hypoglycemia (Hirata's disease).

European journal of clinical nutrition·2015
Same author

Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.

Thrombosis research·2014
Same author

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006.

Haemophilia : the official journal of the World Federation of Hemophilia·2009
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Area of Science:

  • Hematology
  • Immunology

Background:

  • Factor V inhibitors are rare but serious conditions.
  • Understanding their pathogenesis and clinical course is crucial for patient management.

Purpose of the Study:

  • To review and categorize cases of factor V inhibitors.
  • To describe clinical and biochemical properties.
  • To evaluate prognosis and treatment options.

Main Methods:

  • Literature review of 105 cases published between 1955 and 1997.
  • Classification of patients into five etiological groups.
  • Analysis of clinical presentation, biochemical data, and outcomes.

Main Results:

  • Five etiological groups identified: bovine thrombin exposure, post-surgery, miscellaneous conditions, idiopathic, and congenital factor V deficiency.

Related Experiment Videos

  • Overall prognosis is favorable, but 'idiopathic' inhibitors have the worst outcome.
  • Immunoadsorption and plasmapheresis show promise for acute bleeding management.

    • Conclusions:

    • Prognosis for factor V inhibitors is group-dependent.
    • Effective acute bleeding treatments include immunoadsorption and plasmapheresis.
    • Spontaneous resolution is common; immunosuppression efficacy is uncertain.